Nanobiotix ( (NBTX) ) just unveiled an announcement.
Nanobiotix announced the first data from the completed dose escalation part of a Phase 1 study evaluating NBTXR3 (JNJ-1900) as a second or later line therapy for patients with locally advanced non-small cell lung cancer (NSCLC). The study, sponsored by MD Anderson Cancer Center, showed favorable safety and injection feasibility in 12 patients, with promising early efficacy signals. Preliminary survival data indicated a 12-month local progression-free survival of 64% and overall survival of 83%. The expansion phase of the study is ongoing, with 5 out of 12 patients injected so far. These findings suggest NBTXR3 could offer a new therapeutic option for patients with limited alternatives after prior treatments have failed.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, France, and listed on Euronext Paris and Nasdaq. The company focuses on pioneering disruptive, physics-based therapeutic approaches, particularly in oncology, bioavailability, and biodistribution. They own over 25 umbrella patents and have engaged in collaborations to expand their product development, including a notable partnership with The University of Texas MD Anderson Cancer Center.
YTD Price Performance: 18.28%
Average Trading Volume: 15,022
Technical Sentiment Signal: Buy
Current Market Cap: $167.9M
Find detailed analytics on NBTX stock on TipRanks’ Stock Analysis page.